{
    "clinical_study": {
        "@rank": "99144", 
        "arm_group": {
            "arm_group_label": "Askina Calgitrol Paste", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to demonstrate that Askina\u00ae Calgitrol\u00ae Paste is safe to use on\n      III degree burns by quantifying the concentration of silver in the blood during treatment\n      and thus to show that the amount of silver absorbed will be no greater than those reported\n      in the literature."
        }, 
        "brief_title": "Askina Calgitrol Paste Burns", 
        "condition": "Third Degree Burns", 
        "condition_browse": {
            "mesh_term": "Burns"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults (\u2265>18 years age). No upper age limit\n\n          -  III degree thermal burns from 2-30% TBSA as determined by the Rule of Nines\n\n          -  Patients who underwent initial treatment within 24 hours after the injury at the\n             latest\n\n          -  Patients who underwent initial treatment directly at the Burn Centre of FNKV or the\n             initial treatment was in accordance with the standard of care of the Centre\n\n          -  All patients will have been hospitalised\n\n          -  Patients who are capable of giving signing informed consent and have done so.\n\n        Exclusion Criteria:\n\n          -  Patients with electrical or chemical burns\n\n          -  Patients with already infected wounds\n\n          -  Patients taking systemic antibiotics on admission\n\n          -  Patients pregnant or lactating\n\n          -  Patients who fall into \"vulnerable population\" group with respect to informed consent\n             or who are not capable of giving informed consent\n\n          -  Patients who used or were treated with silver products for other reasons than\n             treatment of the acute burn in the last 3 months\n\n          -  Patients whose other burn wounds are being treated with silver products.\n\n          -  Patients receiving renal dialysis\n\n          -  Known allergy or sensitivity to any of the ingredients in Askina\u00ae Calgitrol\u00ae Paste.\n\n          -  Simultaneous participation in another interventional clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911858", 
            "org_study_id": "OPM-G-H-1204"
        }, 
        "intervention": {
            "arm_group_label": "Askina Calgitrol Paste", 
            "intervention_name": "Askina Calgitrol Paste", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 29, 2013", 
        "number_of_arms": "1", 
        "official_title": "Non-controlled Prospective Cohort Study of the Use of Askina\u00ae Calgitrol\u00ae Paste on III Degree Burns in Adults", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The quantification of the amount of silver found in plasma during the treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Change from Baseline in Blood at 3 days"
            }, 
            {
                "measure": "The quantification of the amount of silver found in plasma during the treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Change from Baseline in Blood immediately after the removal of the last investigational dressing (the day before necrotomy, an expected average between 3-10 days after inclusion)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911858"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Data will not be recorded at specific time points due to individual changing patterns. The investigator will make a subjective description of the wound bed covered by necrosis, slough/fibrin, granulation tissue and epithelialisation and by the condition of the peri-wound skin.", 
                "measure": "Wound bed and periwound skin conditions", 
                "safety_issue": "Yes", 
                "time_frame": "At each dressing change (an expected average of one day)"
            }, 
            {
                "description": "Data will not be recorded at specific time points due to individual changing patterns.\nThe presence and intensity of clinical signs of infection will be assessed at the start of the study and at each dressing change using clinical judgment and a scoring system modified from the one published by Trial and al.", 
                "measure": "Clinical signs of infection", 
                "safety_issue": "Yes", 
                "time_frame": "At each dressing change (an expected average of one day)"
            }, 
            {
                "description": "Data will not be recorded at specific time points due to individual changing patterns.\nThe investigator will complete a Likert scale score  (1-4, Poor, Fair, Good, Excellent) for each ease of application and ease of removal of Askina Calgitrol Paste at each dressing change.", 
                "measure": "Patient comfort", 
                "safety_issue": "No", 
                "time_frame": "At each dressing change (an expected average of one day)"
            }, 
            {
                "description": "Data will not be recorded at specific time points due to individual changing patterns.", 
                "measure": "Number of dressing changes", 
                "safety_issue": "No", 
                "time_frame": "At each dressing change (an expected average of one day)"
            }, 
            {
                "measure": "Adverse Events or Adverse device related event", 
                "safety_issue": "Yes", 
                "time_frame": "At each dressing change"
            }
        ], 
        "source": "BBraun Medical SAS", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BBraun Medical SAS", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}